2017
DOI: 10.1002/acn3.434
|View full text |Cite
|
Sign up to set email alerts
|

Sensorimotor rhythm neurofeedback as adjunct therapy for Parkinson's disease

Abstract: Neurofeedback may enhance compensatory brain mechanisms. EEG‐based sensorimotor rhythm neurofeedback training was suggested to be beneficial in Parkinson's disease. In a placebo‐controlled study in parkinsonian nonhuman primates we here show that sensorimotor rhythm neurofeedback training reduces MPTP‐induced parkinsonian symptoms and both ON and OFF scores during classical L‐DOPA treatment. Our findings encourage further development of sensorimotor rhythm neurofeedback training as adjunct therapy for Parkinso… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
29
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
5
3
1

Relationship

3
6

Authors

Journals

citations
Cited by 22 publications
(29 citation statements)
references
References 23 publications
0
29
0
Order By: Relevance
“…Also, quantities assessing the interaction of brain oscillation, e.g., phase amplitude coupling (PAC) might be used as biomarker to represent the amount of symptoms (Beudel and Brown, 2016 ). Also, activity in the beta band might be relevant for compensatory purposes, as recently shown in a parkinsonian monkey study with sensorimotor rhythm neurofeedback (Philippens et al, 2017 ).…”
Section: Discussionmentioning
confidence: 83%
“…Also, quantities assessing the interaction of brain oscillation, e.g., phase amplitude coupling (PAC) might be used as biomarker to represent the amount of symptoms (Beudel and Brown, 2016 ). Also, activity in the beta band might be relevant for compensatory purposes, as recently shown in a parkinsonian monkey study with sensorimotor rhythm neurofeedback (Philippens et al, 2017 ).…”
Section: Discussionmentioning
confidence: 83%
“…However, for instance in Parkinson’s disease it is still a matter of debate whether there is a measurable quantity that reasonably represents the extent of symptoms, in a biomarker-like manner [ 126 , 127 ]. In fact, a number of studies provided results that are in contradiction of the biomarker notion [ 127 133 ]. Accordingly, so far, it is not possible to provide ranges of the amount of synchrony–reflected by R av —that correspond to physiological as opposed to abnormal, Parkinsonian states.…”
Section: Discussionmentioning
confidence: 99%
“…Also, beta band oscillations need not be entirely pathological. Rather activity in the beta frequency range might be key for compensatory purposes, as demonstrated in an MPTP monkey study with sensorimotor rhythm neurofeedback (Philippens et al, 2017 ).…”
Section: Discussionmentioning
confidence: 99%
“…In contrast, MLDF requires a reliably measurable clean biomarker signal sufficiently representing the amount of abnormal synchronization. Despite first positive results (Little et al, 2013 ; Rosa et al, 2015 ), several findings indicate that beta-band STN LFP does not provide a reliable biomarker (Özkurt et al, 2011 ; Quinn et al, 2015 ; Johnson et al, 2016 ; Kühn and Volkmann, 2017 ; Philippens et al, 2017 ), see above. In addition, MLDF requires a challenging registration-stimulation setup: An LFP signal, representative for the entire neuronal target population, has to be measured at one site, while stimuli have to be delivered to different sites of the target population.…”
Section: Discussionmentioning
confidence: 99%